$92.2 Million is the total value of CAXTON CORP's 24 reported holdings in Q1 2018. The portfolio turnover from Q4 2017 to Q1 2018 was 45.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SBBP | Sell | STRONGBRIDGE BIOPHARMA PLC | $47,309,000 | +18.3% | 5,376,039 | -2.5% | 51.34% | +5.6% |
| Buy | GARRISON CAP INC | $9,054,000 | +11.6% | 1,115,072 | +11.5% | 9.83% | -0.3% | |
| MTEM | Buy | MOLECULAR TEMPLATES INC | $8,310,000 | -18.2% | 1,038,787 | +2.5% | 9.02% | -27.0% |
| CMFN | Buy | CM FIN INC | $6,640,000 | +1056.8% | 809,772 | +1050.2% | 7.21% | +932.4% |
| SCYX | New | SCYNEXIS INCwarrant | $6,526,000 | – | 4,870,409 | +100.0% | 7.08% | – |
| AGRX | Sell | AGILE THERAPEUTICS INC | $4,664,000 | -4.7% | 1,814,949 | -0.3% | 5.06% | -15.0% |
| BRKB | Buy | BERKSHIRE HATHAWAY INC DELcl b new | $1,858,000 | +4.8% | 9,312 | +4.1% | 2.02% | -6.5% |
| JBGS | JBG SMITH PPTYS | $1,388,000 | -2.9% | 41,170 | 0.0% | 1.51% | -13.3% | |
| PCG | New | PG&E CORP | $988,000 | – | 22,500 | +100.0% | 1.07% | – |
| UHAL | New | AMERCO | $932,000 | – | 2,700 | +100.0% | 1.01% | – |
| GTXI | Sell | GTX INC DEL | $877,000 | +9.8% | 49,393 | -21.4% | 0.95% | -2.0% |
| TCAP | Buy | TRIANGLE CAP CORP | $543,000 | +41.0% | 48,831 | +20.3% | 0.59% | +25.9% |
| FSK | Buy | FS INVT CORP | $508,000 | +124.8% | 70,115 | +128.3% | 0.55% | +100.4% |
| BUD | New | ANHEUSER BUSCH INBEV SA/NVsponsored adr | $486,000 | – | 4,425 | +100.0% | 0.53% | – |
| ABDC | Buy | ALCENTRA CAP CORP | $446,000 | -10.8% | 64,136 | +7.7% | 0.48% | -20.4% |
| Sell | INTEC PHARMA LTD JERUSALEM | $395,000 | +5.3% | 64,280 | -11.7% | 0.43% | -5.9% | |
| ACRS | Buy | ACLARIS THERAPEUTICS INC | $370,000 | -16.7% | 21,142 | +17.5% | 0.40% | -25.6% |
| MDGL | Sell | MADRIGAL PHARMACEUTICALS INC | $233,000 | +5.0% | 1,999 | -17.3% | 0.25% | -6.3% |
| ADNT | Sell | ADIENT PLC | $229,000 | -38.6% | 3,838 | -19.0% | 0.25% | -45.0% |
| DRNA | New | DICERNA PHARMACEUTICALS INC | $125,000 | – | 13,074 | +100.0% | 0.14% | – |
| MRNS | Buy | MARINUS PHARMACEUTICALS INC | $102,000 | -32.9% | 26,827 | +43.9% | 0.11% | -40.0% |
| CPRX | Buy | CATALYST PHARMACEUTICALS INC | $86,000 | -33.3% | 36,079 | +9.0% | 0.09% | -40.8% |
| SRRA | New | SIERRA ONCOLOGY INC | $78,000 | – | 37,582 | +100.0% | 0.08% | – |
| SPY | Exit | SPDR S&P 500 ETF TRput | $0 | – | -2,519 | -100.0% | -0.82% | – |
| IWM | Exit | ISHARES TRcall | $0 | – | -6,540 | -100.0% | -1.21% | – |
| KALA | Exit | KALA PHARMACEUTICALS INC | $0 | – | -544,220 | -100.0% | -12.23% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MOLECULAR TEMPLATES INC | 24 | Q2 2023 | 30.7% |
| STRONGBRIDGE BIOPHARMA PLC | 22 | Q3 2021 | 73.1% |
| GARRISON CAP INC | 18 | Q3 2020 | 9.9% |
| BERKSHIRE HATHAWAY INC DEL | 17 | Q3 2019 | 5.8% |
| EIGER BIOPHARMACEUTICALS INC | 17 | Q3 2022 | 1.7% |
| AGILE THERAPEUTICS INC | 16 | Q1 2018 | 55.5% |
| KALA PHARNACEUTICALS INC | 16 | Q4 2021 | 17.6% |
| CM FIN INC | 16 | Q1 2019 | 7.8% |
| SYNTA PHARMACEUTICALS CORP | 15 | Q2 2016 | 99.9% |
| CTI BIOPHARMA CORP | 14 | Q4 2021 | 8.7% |
View CAXTON CORP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Addex Therapeutics Ltd. | February 14, 2023 | 718,849 | 0.9% |
| Cardiff Oncology, Inc. | February 14, 2023 | 983,607 | 2.2% |
| Rezolute, Inc. | February 14, 2023 | 1,860,518 | 5.0% |
| Xeris Biopharma Holdings, Inc. | February 14, 2023 | 5,973,324 | 4.4% |
| CTI BIOPHARMA CORP | February 14, 2022 | 2,239,300 | 2.3% |
| Sierra Oncology, Inc. | February 14, 2022 | 1,119,322 | 7.0% |
| Strongbridge Biopharma plcSold out | January 05, 2022 | 0 | 0.0% |
| SUNESIS PHARMACEUTICALS INCSold out | February 16, 2021 | 0 | 0.0% |
| Alcentra Capital Corp | February 14, 2020 | 1,005,000 | 7.8% |
| Garrison Capital Inc. | February 14, 2020 | 1,223,096 | 7.6% |
View CAXTON CORP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
View CAXTON CORP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.